Evaluation of Gremlin-1 as a Therapeutic Target in Metabolic Dysfunction-Associated Steatohepatitis: Lack of Efficacy Despite Increased Hepatic Expression
Hepatic Gremlin-1 expression is increased in metabolic dysfunction-associated steatohepatitis (MASH), but therapeutic targeting of Gremlin-1 does not reduce liver inflammation or fibrosis in in vivo and ex vivo models.